| Keith R Stephenson, MD | |
|
2900 Lamb Cir, Suite 300, Christiansburg, VA 24073-6344 | |
| (540) 639-5900 | |
| (540) 639-0976 |
| Full Name | Keith R Stephenson |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 41 Years |
| Location | 2900 Lamb Cir, Christiansburg, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598746018 | NPI | - | NPPES |
| 007313420 | Medicaid | VA | |
| 010269024 | Medicaid | VA | |
| 007313411 | Medicaid | VA | |
| 007313560 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 0101-233788 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carilion New River Valley Medical Center | Christiansburg, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carilion Healthcare Corporation | 5890607253 | 408 |
News Archive
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
Researchers highlight the potential causes of some COVID-19 symptoms. Early in the pandemic, the hallmark symptoms of COVID-19 include cough, fever, and shortness of breath. As the pandemic has evolved, more symptoms have emerged, such as loss of smell and taste, headache, intestinal issues, and abdominal pains.
Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has agreed to acquire the rights to several prescription and cosmetic dermatology products from a privately-held, Polish specialty pharmaceutical company.
Nuveta, Inc., a privately held medical device company and global leader in basic in vitro fertilization (IVF) research, announced today that it has closed a Series A seed financing round, solely funded by Vivo Ventures.
Intellikine announced today the publication of an article entitled, "The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors," now available as an advanced online publication at Nature Chemical Biology.
› Verified 3 days ago
| Entity Name | Carilion Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206370 PECOS PAC ID: 5890607253 Enrollment ID: O20031106000273 |
News Archive
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
Researchers highlight the potential causes of some COVID-19 symptoms. Early in the pandemic, the hallmark symptoms of COVID-19 include cough, fever, and shortness of breath. As the pandemic has evolved, more symptoms have emerged, such as loss of smell and taste, headache, intestinal issues, and abdominal pains.
Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has agreed to acquire the rights to several prescription and cosmetic dermatology products from a privately-held, Polish specialty pharmaceutical company.
Nuveta, Inc., a privately held medical device company and global leader in basic in vitro fertilization (IVF) research, announced today that it has closed a Series A seed financing round, solely funded by Vivo Ventures.
Intellikine announced today the publication of an article entitled, "The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors," now available as an advanced online publication at Nature Chemical Biology.
› Verified 3 days ago
| Entity Name | Carilion New River Valley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316000516 PECOS PAC ID: 5799694964 Enrollment ID: O20031218000611 |
News Archive
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
Researchers highlight the potential causes of some COVID-19 symptoms. Early in the pandemic, the hallmark symptoms of COVID-19 include cough, fever, and shortness of breath. As the pandemic has evolved, more symptoms have emerged, such as loss of smell and taste, headache, intestinal issues, and abdominal pains.
Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has agreed to acquire the rights to several prescription and cosmetic dermatology products from a privately-held, Polish specialty pharmaceutical company.
Nuveta, Inc., a privately held medical device company and global leader in basic in vitro fertilization (IVF) research, announced today that it has closed a Series A seed financing round, solely funded by Vivo Ventures.
Intellikine announced today the publication of an article entitled, "The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors," now available as an advanced online publication at Nature Chemical Biology.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Keith R Stephenson, MD 301 Craig Dr, Blacksburg, VA 24060-1830 Ph: () - | Keith R Stephenson, MD 2900 Lamb Cir, Suite 300, Christiansburg, VA 24073-6344 Ph: (540) 639-5900 |
News Archive
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
Researchers highlight the potential causes of some COVID-19 symptoms. Early in the pandemic, the hallmark symptoms of COVID-19 include cough, fever, and shortness of breath. As the pandemic has evolved, more symptoms have emerged, such as loss of smell and taste, headache, intestinal issues, and abdominal pains.
Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has agreed to acquire the rights to several prescription and cosmetic dermatology products from a privately-held, Polish specialty pharmaceutical company.
Nuveta, Inc., a privately held medical device company and global leader in basic in vitro fertilization (IVF) research, announced today that it has closed a Series A seed financing round, solely funded by Vivo Ventures.
Intellikine announced today the publication of an article entitled, "The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors," now available as an advanced online publication at Nature Chemical Biology.
› Verified 3 days ago
Dr. Charles D Bissell, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2900 Lamb Cir, Suite 300, Christiansburg, VA 24073 Phone: 540-639-5900 Fax: 540-639-0976 | |
Dr. Alex A Tan, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2900 Lamb Cir, Suite 300, Christiansburg, VA 24073 Phone: 540-639-5900 Fax: 540-639-0976 | |
Charles A Harris, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2900 Lamb Cir, Suite 302, Christiansburg, VA 24073 Phone: 540-731-7600 Fax: 540-639-5400 | |
Dr. Ashish Raju, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2900 Lamb Cir, Suite 301, Christiansburg, VA 24073 Phone: 540-731-7600 | |
Lamiere Joseph Downing, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2900 Lamb Cir, Suite 300, Christiansburg, VA 24073 Phone: 540-639-5900 | |
Dr. Caleb Pagliasotti, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 2900 Tyler Rd, Christiansburg, VA 24073 Phone: 540-731-7314 |